1. Home
  2. LABP

LABP

Landos Biopharma Inc.

Logo Landos Biopharma Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages. The company's pipeline includes NX-13, LABP-66, LAPB-73, LABP-69. The company's current focus and lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist.

Founded: 2017 Country:
United States
United States
Employees: N/A City: BLACKSBURG
Market Cap: 67.1M IPO Year: 2021
Target Price: $20.42 AVG Volume (30 days): 25.5K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.50 EPS Growth: N/A
52 Week Low/High: $2.50 - $21.87 Next Earning Date: 05-10-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: